Yu Lab
- People
- Dr. Yu's Research
- Dr. Batova's Research
- Dr. Diccianni's Research
- Publications
- Contact
Dr. Batova is particularly interested in investigating the mechanism of action of natural products with selective cytotoxicity to cancer cells with the intention of discovering novel agents and molecular targets to treat refractory cancers.
Natural products have been a great source of many small molecule drugs for various diseases as more than 70% of the current small molecule therapeutics derive their structures from plants used in traditional medicine. The caged Garcinia xanthones is a family of plant metabolites that possess a unique chemical structure, potent bioactivity, and a promising pharmacology for drug design and development. A member of this family, gambogic acid (GA), has shown significant potential as an anticancer agent with its ability to induce apoptosis in multiple tumor cell lines, including multidrug-resistant cell lines, as well as displaying antitumor activity in animal models. Dr. Batova and her collaborators were the first to demonstrate that the primary target of GA is mitochondria as opposed to the transferrin receptor as originally thought. Their results showed that GA induced mitochondrial damage resulting in fragmentation of the mitochondria (Figure). With these results, Dr. Batova identified GA and cluvenone as new members of mitocans, anticancer agents that act on mitochondria. Specific mitochondrial targets of cluvenone are currently under investigation as well as targets for another natural product, englerin, with highly selective cytotoxicity for renal cancer cells.
GA induces immediate mitochondrial fragmentation which results in apoptosis